Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $360.00

by · The Markets Daily

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target lifted by BMO Capital Markets from $300.00 to $360.00 in a report released on Tuesday,Benzinga reports. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

ALNY has been the subject of several other reports. HC Wainwright restated a “buy” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an “overweight” rating in a research note on Thursday, June 12th. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. Chardan Capital raised their price objective on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty have issued a buy rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $337.91.

Read Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $318.25 on Tuesday. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The company has a market cap of $41.50 billion, a PE ratio of -152.27 and a beta of 0.22. The business has a 50-day simple moving average of $284.47 and a two-hundred day simple moving average of $262.79. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $326.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. Alnylam Pharmaceuticals’s revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer now owns 48,948 shares of the company’s stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC boosted its stake in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the last quarter. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $27,000. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $28,000. Whipplewood Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 71 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Stories